背景:甲状腺癌发病率上升,尤其是甲状腺乳头状癌(PTC),强调了改进诊断方法和管理策略的必要性。在这里,我们的目标是全面回顾甲状腺癌诊断中不断发展的前景以及基于镓-68(Ga-68)的生长抑素受体成像的潜在效用.
方法:通过查看以下文献数据库,我们回顾了涉及基于Ga-68的放射性示踪剂的临床研究-PUBMED,EMBASE,WEB的科学和COCHRANE。我们采用了详细的搜索策略,包括以下搜索词;PubMed:(“镓Ga68dotatate”[补充概念])和(“甲状腺腺体”[网格]或“甲状腺结节”[网格]或“甲状腺肿瘤”[网格]),Embase(“镓68”和“甲状腺疾病”),科学网:(“68镓和甲状腺”)。
结果:Ga-68DOTATATE和Ga-68DOTANOC之间的比较显示出相似的敏感性,但对Ga-68DOTATATE的摄取更高。比较基于Ga-68的SSTRPET和FDGPET的研究强调了这两种方法的潜在优势。基于Ga-68的SSTRPET在某些情况下更具体。
结论:基于Ga-68的生长抑素受体成像在RAI-RDTC中显示出临床实用性,为检测骨骼淋巴结转移提供有价值的见解。值得注意的是,它显示出作为主要成像工具的潜力,可能增强FDGPET的作用。然而,SSTRPET显像鉴别甲状腺良恶性结节的疗效各不相同,影响其特异性的因素复杂的相互作用,指示其作为现有方法的辅助值,保证进一步研究在甲状腺癌管理中的精细作用。
结论:尽管研究存在差异,基于Ga的生长抑素受体成像在甲状腺癌诊断中具有作为诊断方法的补充工具的潜力,与RAI-RDTC特别相关。在精心挑选的患者中,证明存在Ga-68DOTATATE狂热病变,进一步探索,并对Lu177DOTATATE的潜在利用进行调查。
BACKGROUND: The rise in thyroid cancer incidence, especially papillary thyroid cancer (PTC), has underscored the need for improved diagnostic methods and management strategies. Herein, we aim to comprehensively review the evolving landscape in thyroid cancer diagnosis and the potential utility of Gallium-68 (Ga-68) based somatostatin receptor imaging.
METHODS: We reviewed the clinical studies involving Ga-68 based radiotracers by looking at the following literature databases -PUBMED, EMBASE, WEB OF SCIENCE and COCHRANE. We employed a detailed search strategy with the following search terms; PubMed: (\"gallium Ga 68 dotatate\" [Supplementary Concept]) AND (\"Thyroid Gland\"[Mesh] OR \"Thyroid Nodule\"[Mesh] OR \"Thyroid Neoplasms\"[Mesh]), Embase (\"gallium 68\" AND \"Thyroid Disease\"), Web of Science: (\"Gallium 68 and Thyroid\").
RESULTS: A comparison between Ga-68 DOTATATE and Ga-68 DOTANOC showed similar sensitivities but a higher uptake for Ga-68 DOTATATE. Studies comparing Ga-68-based SSTR PET with FDG PET highlighted the potential advantages of both approaches, with Ga-68-based SSTR PET being more specific in certain cases.
CONCLUSIONS: Ga-68-based somatostatin receptor imaging displays clinical utility in RAI-R DTC, offering valuable insight into detecting skeletal lymph node metastases. Notably, it shows potential as a primary imaging tool, potentially augmenting the role of FDG PET. However, SSTR PET imaging\'s efficacy in distinguishing benign from malignant thyroid nodules varies, with a complex interplay of factors influencing its specificity, indicating its value as an adjunct to existing methods, warranting further research for a refined role in thyroid cancer management.
CONCLUSIONS: Although study variations exist, Ga-based somatostatin receptor imaging holds potential as a complementary tool alongside diagnostic methods in thyroid cancer diagnosis, with particular relevance to RAI-R DTC. In carefully selected patients demonstrating the presence of Ga-68 DOTATATE avid lesions, further exploration, and investigation into the potential utilization of Lu177 DOTATATE are warranted.